The Science Behind Medical Weight Loss
Medically reviewed by the LeoCore Health clinical team · Last reviewed October 21, 2026
Evidence-based education on GLP-1 medications, candidacy, side effects, and what to expect — for informational purposes only.
Sustainable weight loss is rarely about willpower alone. Modern research shows that body weight is regulated by complex hormonal, metabolic, and neurological systems — many of which can be directly addressed through physician-supervised treatment. GLP-1 receptor agonist medications represent one of the most significant advances in obesity medicine in decades, and understanding how they work can help you have a more informed conversation with a licensed provider.
How GLP-1 Medications Work
GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating. It signals the brain to reduce appetite, slows the rate at which the stomach empties, and stimulates the pancreas to release insulin in response to rising blood sugar. GLP-1 receptor agonists are synthetic compounds that mimic this hormone — binding to the same receptors and producing the same effects, but with a much longer duration of action than the body's own GLP-1.
Semaglutide (the active ingredient in Ozempic® and Wegovy®) and tirzepatide (the active ingredient in Mounjaro® and Zepbound®) are the two most studied agents in this class. Tirzepatide also activates GIP (glucose-dependent insulinotropic polypeptide) receptors, which may contribute to its stronger effect on body weight seen in clinical trials. Both medications are administered as once-weekly subcutaneous injections.
These medications do not work by suppressing metabolism or causing the body to burn fat directly. Their primary mechanism is appetite regulation — patients typically report significantly reduced hunger and fewer food cravings, which leads to lower caloric intake over time. Weight loss is a downstream result of that reduced intake, not a direct pharmacological effect.
Who May Be a Candidate — and Who Should Not Use These Medications
A licensed provider will evaluate your full health history before recommending any treatment. In general, GLP-1 medications are considered for adults who:
Have a BMI of 30 or higher (obesity), or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol
Have not achieved adequate weight loss through diet and exercise alone
Do not have contraindicated medical conditions (see below)
Are not pregnant or planning to become pregnant during treatment
These medications are generally not appropriate for people who have:
A personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
A history of pancreatitis
Severe gastrointestinal disease
Certain kidney or liver conditions, depending on severity
Known hypersensitivity to semaglutide, tirzepatide, or any component of the formulation
This list is not exhaustive. Only a licensed healthcare provider can determine whether a medication is appropriate for you based on your complete medical history.
Common Side Effects and How Providers Manage Them
GLP-1 medications are generally well tolerated, but side effects are common — particularly during the dose escalation phase. Understanding what to expect can help you prepare and communicate effectively with your provider.
Nausea: The most frequently reported side effect, especially in the first few weeks. It typically improves as the body adjusts. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help.
Vomiting and diarrhea: Less common than nausea but reported by some patients. Usually transient and manageable with dietary adjustments.
Constipation: Occurs in some patients due to slowed gastric motility. Increased fiber intake and hydration are typically recommended.
Fatigue: Some patients report low energy early in treatment, often related to reduced caloric intake. This generally resolves as the body adapts.
Injection site reactions: Mild redness, itching, or bruising at the injection site. Rotating injection sites helps minimize this.
Providers typically use a slow dose-escalation schedule — starting at the lowest available dose and increasing gradually over several weeks — to reduce the severity of gastrointestinal side effects. If side effects are significant, a provider may slow the titration schedule or adjust the treatment plan. Patients should always contact their provider before stopping medication.
Serious adverse events are rare but possible. These include pancreatitis, gallbladder disease, and — based on animal studies — a potential risk of thyroid C-cell tumors (which is why these medications carry a boxed warning for patients with a history of MTC or MEN 2). Patients should seek immediate medical attention for severe abdominal pain, persistent vomiting, or signs of an allergic reaction.
What to Expect Week by Week
Individual responses to GLP-1 medications vary. The following is a general educational overview based on clinical trial data and published literature — not a prediction of any individual's results.
Weeks 1–4 (Starting dose)
Most patients begin at the lowest dose. Nausea is most common during this phase. Appetite reduction may begin within the first week for some patients, though noticeable weight changes are typically modest at this stage.
Weeks 5–12 (Dose escalation)
Doses are typically increased every four weeks according to the prescribing protocol. Appetite suppression generally becomes more pronounced. Gastrointestinal side effects often improve as the body adjusts.
Months 3–6 (Therapeutic dose)
Many patients reach their maintenance dose during this period. Clinical trials show the most significant weight loss occurring between months three and six. Energy levels and metabolic markers often begin to improve.
Months 6–12+ (Ongoing treatment)
Weight loss may continue or plateau depending on the individual. Ongoing provider check-ins support dose adjustments, lifestyle coaching, and long-term adherence. Clinical data suggests that continued treatment is associated with sustained results.
These timelines are based on published clinical trial data and are provided for educational purposes only. Individual results vary and are not guaranteed.
Compounded vs. Brand-Name Medication
Patients often ask about the difference between brand-name GLP-1 medications (such as Wegovy® and Zepbound®) and compounded versions. Understanding this distinction is important.
Brand-name medications
Brand-name semaglutide and tirzepatide products are FDA-approved drugs that have undergone rigorous clinical trials for safety, efficacy, and manufacturing quality. They are produced by licensed pharmaceutical manufacturers under strict FDA oversight.
Compounded medications
Compounded semaglutide and tirzepatide are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities. Compounded medications are not FDA-approved — they are not evaluated by the FDA for safety, efficacy, or quality in the same way brand-name drugs are. Compounding is legally permitted under specific circumstances, including when an FDA-approved drug is on the FDA shortage list or when a patient has a documented medical need that cannot be met by a commercially available product.
LeoCore Health's clinical partner works exclusively with licensed US-based 503A compounding pharmacies and FDA-registered 503B outsourcing facilities. Patients should discuss the specific medication being prescribed — including whether it is compounded or brand-name — directly with their licensed provider.
The FDA has published guidance on compounded GLP-1 medications. Patients are encouraged to review the FDA's resources directly for the most current regulatory information.
Frequently Asked Questions
Do I need a prescription for GLP-1 weight loss medications?
Yes. Semaglutide and tirzepatide are prescription medications. A licensed healthcare provider must evaluate your health history and determine whether a prescription is medically appropriate for you. LeoCore Health connects patients with independent licensed providers through its clinical partner's HIPAA-compliant telehealth portal.
How long do I need to stay on the medication?
The appropriate duration of treatment depends on your individual health goals and your provider's clinical judgment. Clinical research suggests that weight regain is common after stopping GLP-1 medications, which is why ongoing provider support and lifestyle changes are an important part of any treatment plan. Your provider will discuss the right approach for your situation.
Are these medications covered by insurance?
Insurance coverage for GLP-1 weight loss medications varies widely by plan and is not guaranteed. Many insurance plans do not cover these medications for weight management specifically, even when they cover the same drugs for type 2 diabetes. LeoCore Health's pricing page provides transparent starting prices for compounded medication programs.
What is the difference between Semaglutide and Tirzepatide?
Both are GLP-1 receptor agonists used for weight management, but tirzepatide also activates GIP receptors, making it a dual agonist. Clinical trials have shown tirzepatide to produce greater average weight loss than semaglutide in head-to-head comparisons, though individual responses vary. A licensed provider can help determine which medication may be more appropriate based on your health history.
Can I use these medications if I have type 2 diabetes?
GLP-1 medications were originally developed for type 2 diabetes management and are FDA-approved for that indication. However, whether they are appropriate for you specifically — and at what dose — depends on your complete medical history, current medications, and other factors. A licensed provider must evaluate your individual situation before prescribing.
Sources
FDA: Wegovy (semaglutide) prescribing information
FDA: Zepbound (tirzepatide) prescribing information
Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.
FDA: Compounding and the FDA — Questions and Answers
Ready to Take the Next Step?
Start with a confidential online evaluation. A licensed provider will review your health history and goals to determine whether treatment may be appropriate for you.
Comments